Bictegravir
規格
1611493-60-7CAS番号
(1S,11R,13R)-5-hydroxy-3,6-dioxo-N-[(2,4,6-trifluorophenyl)methyl]-12-oxa-2,9-diazatetracyclo[11.2.1.02,11.04,9]hexadeca-4,7-diene-7-carboxamideIUPAC名
C21H18F3N3O5化学式
449.4 g/mol分子量
Bictegravir; 1611493-60-7; GS-9883; bictegravirum; GS-9883-01; 8GB79LOJ07; (1S,11R,13R)-5-hydroxy-3,6-dioxo-N-[(2,4,6-trifluorophenyl)methyl]-12-oxa-2,9-diazatetracyclo[11.2.1.02,11.04,9]hexadeca-4,7-diene-7-carboxamide; CHEBI:172943; DTXSID701027937; 2,5-Methanopyrido(1',2':4,5)pyrazino(2,1-b)(1,3)oxazepine-10-carboxamide, 2,3,4,5,7,9,13,13a-octahydro-8-hydroxy-7,9-dioxo-N-((2,4,6-trifluorophenyl)methyl)-, (2R,5S,13aR)-; 2,5-Methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide, 2,3,4,5,7,9,13,13a-octahydro-8-hydroxy-7,9-dioxo-N-[(2,4,6-trifluorophenyl)methyl]-, (2R,5S,13aR)-; (1S,11R,13R)-5-hydroxy-3,6-dioxo-N-((2,4,6-trifluorophenyl)methyl)-12-oxa-2,9-diazatetracyclo(11.2.1.02,11.04,9)hexadeca-4,7-diene-7-carboxamide; (2R,5S,13aR)-2,3,4,5,7,9,13,13a-Octahydro-8-hydroxy-7,9-dioxo-N-((2,4,6-trifluorophenyl)methyl)-2,5-methanopyrido(1',2':4,5)pyrazino(2,1-b)(1,3)oxazepine-10-carboxamide; (2R,5S,13aR)-2,3,4,5,7,9,13,13a-Octahydro-8-hydroxy-7,9-dioxo-N-[(2,4,6-trifluorophenyl)methyl]-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide; RefChem:568041; DTXCID901513504; (2R,5S,13aR)-8-hydroxy-7,9-dioxo-N-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide; Bictegravir [INN]; GS 9883; Bictegravir (100 mg/mL in DMSO); Bictegravir [USAN:INN]; UNII-8GB79LOJ07; Bictegravin; Bictegravir?; C21H18F3N3O5; MFCD31536971; Bictegravir (Standard); BICTEGRAVIR [MI]; Bictegravir (USAN/INN); Bictegravir, (+/-)-; BICTEGRAVIR [USAN]; RY7J24S9ZL; BICTEGRAVIR [WHO-DD]; CHEMBL3989866; SCHEMBL15914278; GTPL11575; SOLUWJRYJLAZCX-LYOVBCGYSA-N; BDBM330048; EX-A3161; EBC-27122; GS9883; HY-17605R; s5911; AKOS032954062; DB11799; DT-0020; AC-30658; DA-51105; HY-17605; NB166284; CS-0014685; NS00073631; D10909; N16998; US9663528, 42; EN300-22793610; F805020; Q27270406; (1S,11R,13R)-5-hydroxy-3,6-dioxo-N-[(2,4,6-trifluorophenyl)methyl]-12-oxa-2,9-diazatetracyclo[11.2.1.0(2),(1)(1).0?,?]hexadeca-4,7-diene-7-carboxamide; (1S,11R,13R)-5-hydroxy-3,6-dioxo-N-[(2,4,6-trifluorophenyl)methyl]-12-oxa-2,9-diazatetracyclo[11.2.1.0^{2,11}.0^{4,9}]hexadeca-4,7-diene-7-carboxamide; (2R, 5S, 13aR) - 8- Hydroxy- 7, 9- dioxo- N- (2, 4, 6- trifluorobenzyl) - 2, 3, 4, 5, 7, 9, 13, 13a- octahydro- 2, 5- methan opyrido[1', 2':4, 5] pyrazino[2, 1- b] [1, 3] oxazepine- 10- carboxamide; (2R,5S,13aR)-8-hydroxy-7,9-dioxo-N-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2, 1-b][1,3]oxazepine-10-carboxamide; (2RS,5SR,13aRS)-2,3,4,5,7,9,13,13a-Octahydro-8-hydroxy-7,9-dioxo-N-[(2,4,6-trifluorophenyl)methyl]-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide; 2,5-Methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide, 2,3,4,5,7,9,13,13a-octahydro-8-hydroxy-7,9-dioxo-N-[(2,4,6-trifluorophenyl)methyl]-, (2R,5S,13aR)-rel-; rel-(2R,5S,13aR)-2,3,4,5,7,9,13,13a-Octahydro-8-hydroxy-7,9-dioxo-N-[(2,4,6-trifluorophenyl)methyl]-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide別名
